BACKGROUND: Golimumab is a @entity310 -blocking agent indicated as a second-line therapy in @entity31 . PURPOSE: To research the effectiveness and safety of golimumab in @entity1 with @entity31 in clinical practice. METHODS: Retrospective study of the effectiveness and safety of golimumab in @entity1 with @entity31 . All @entity1 received golimumab 200 mg subcutaneously at week 0, and golimumab 100 mg subcutaneously at week 2. After the induction treatment, each @entity1 received 50 mg sc. every 4 weeks in @entity1 with body weight less than 80 kg, and 100 mg every 4 weeks in @entity1 with body weight greater than or equal to 80 kg. RESULTS: Study of a group of 23 @entity31 @entity1 , 7 of whom were naive to any anti- @entity310 therapy, and 16 @entity1 who had previously been treated with an anti- @entity310 agent other than golimumab (non-naive @entity1 ). The average treatment time with golimumab was 14.3 weeks. Globally, withdrawal of @entity288 was observed in 74% of cases. Clinical response was observed in 85.5% of @entity1 who had not received biological treatment previously, and in @entity1 who had previously received biological treatment the response rate was 75%. CONCLUSIONS: In this short study, golimumab seems to be an alternative treatment in naive and non-naive anti- @entity310 @entity31 @entity1 . It is also a safe therapy, given that there were no adverse effects in the @entity1 studied.

Initial experience with golimumab in clinical practice for XXXX .

@entity310 :: ('7124', 'Gene') :: ['TNF'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']
